Print

Print


 

Parkinson's Disease: Nicotine Reduces Levodopa-induced Dyskinesias
ScienceDaily (Oct. 24, 2007) — The Parkinson's Institute and Clinical Center 
has announced research showing that intermittent nicotine treatment reduces 
medication-induced dyskinesias by as much as 50 percent in models of 
Parkinson's disease. Levodopa, the most common drug used to treat Parkinson's 
disease, is initially very effective. 

However, long-term treatment often lessens efficacy and causes multiple 
complications, including abnormal involuntary movements, called dyskinesias. 
These uncontrolled movements of the head and limbs tend to worsen over time 
and can become as debilitating as Parkinson's disease itself. 
Currently, there are only limited therapeutic options for dyskinesias, 
including reduction in levodopa dose, amantadine administration, and deep 
brain stimulation for a limited number of patients. 
Most of the research on tobacco has focused on its detrimental health effects. 
Studies conducted over the last 40 years show that the incidence of 
Parkinson's disease is about 50 percent less in smokers than in the general 
population. Recent studies in experimental models suggest that the nicotine 
in smoke may be responsible for this neuroprotective effect. 
In addition, this is the first research to show that nicotine may also reduce 
levodopa-induced dyskinesias. With an estimated 1.5 million Parkinson's 
disease patients in the United States, and levodopa being the top prescribed 
medication for Parkinson's disease, this study has far-reaching implications 
for the treatment of Parkinson's disease. 
"Our hope is that this research represents a useful treatment strategy to 
reduce the dyskinesias that so many Parkinson's disease patients 
suffer, "said Dr. Maryka Quik of the Parkinson's Institute and Clinical 
Center in Sunnyvale. "Reducing the side effects of levodopa makes it a much 
more effective and long-term treatment."
Lead by senior research scientist, Maryka Quik, Ph.D., the research will be 
published in an upcoming issue of the Annals of Neurology.

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn